转移部位不同对广泛期小细胞肺癌胸部放疗价值的影响

doi:10.3760/cma.j.cn113030-20211019-00418

摘要
图/表
参考文献(26)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的分析胸部放疗在不同转移部位的广泛期小细胞肺癌(ES-SCLC)患者中的治疗价值。方法回顾性分析2010—2019年间就诊于天津医科大学肿瘤医院首诊ES-SCLC患者,其中化疗后病情无进展病例 830例纳入分析。所有患者均一线接受了含铂方案化疗,341例患者接受了胸部放疗。主要观察终点为总生存(OS),采用卡方检验对性别、年龄等分类数据进行比较,采用Kaplan-Meier方法计算OS且log-rank检验,用Cox多因素回归分析评估影响患者OS的风险因素。结果与未接受胸部放疗组相比,胸部放疗显著改善了患者的OS (中位OS为15.2个月∶10.8个月,P<0.001)。亚组分析中寡转移组无肝转移患者接受胸部放疗明显改善OS (中位OS为16.0月∶11.4月,P<0.001),有肝转移患者接受胸部放疗OS似乎有所提高(中位OS为14.2个月∶10.6个月,P=0.072)。多发转移组中无肝转移患者胸部放疗后OS明显改善(中位OS为14.5个月∶10.9个月,P<0.001),而有肝转移患者接受胸部放疗预后无明显改善(中位OS为10.2个月∶9.2个月,P=0.715)。结论在ES-SCLC患者中寡转移组无肝转移患者接受胸部放疗OS明显获益,肝转移患者在化疗有效基础上胸部放疗也有可能有生存获益;而在多发转移患者中胸部放疗仅改善了无肝转移患者OS,而未改善有肝转移患者预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	贾惠钧
	马金涛
	孟春柳
	于灏
	罗婧
	徐利明
	刘宁波
	王平
	赵路军

关键词 ：癌,小细胞肺/放射疗法, 远处转移, 预后

Abstract：Objective To evaluate the efficacy and safety of thoracic radiotherapy in the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with different metastatic sites. Methods A retrospective analysis was performed among 830 ES-SCLC patients who were admitted to our hospital from 2010 to 2019. They all received the first-line chemotherapy and had no progression after chemotherapy. 341 patients of them received thoracic radiotherapy after chemotherapy. The main endpoint was overall survival. The Chi-square test was used to compare the categorical data including gender and age, etc. Univariate survival analysis was estimated by Kaplan-Meier method and the log-rank test was used to compare the survival curves between two groups. A multivariate prognostic analysis was made by the Cox proportional hazard model. Results In all the patients, the overall survival (OS) was 12.4 months. The patients with thoracic radiotherapy had significantly higher OS than the patients without thoracic radiotherapy (15.2 months vs.10.8 months,P<0.001). Thoracic radiotherapy significantly improved the OS in patients without liver metastasis (16.0 months vs.11.4 months, P<0.001) in the oligometastatic patients. But for the oligometastatic patients with liver metastasis, the OS benefit was not significant (14.2 months vs. 10.6 months, P=0.072). For polymetastatic patients without liver metastasis, thoracic radiotherapy offered significant OS benefits (14.5 months vs.10.9 months,P<0.001), but for the polymetastatic patients with liver metastasis, the OS was not improved with thoracic radiotherapy (10.2 months vs.9.2 months,P=0.715). Conclusions In ES-SCLC patients, thoracic radiotherapy provides significant OS benefits in patients with oligometastases ES-SCLC without liver metastasis and for the liver metastatic patients may also benefit from thoracic radiotherapy based on the effectiveness of chemotherapy. In patients with multiple metastases, thoracic radiotherapy only improves the OS in patients without liver metastasis, but does not improve the prognosis in patients with liver metastasis.

Key words： Carcinoma, small cell lung/radiotherapy Distant metastasis Prognosis

收稿日期: 2021-10-19

基金资助:国家自然科学基金(81903121)

通讯作者: 赵路军,Email:zhaolujun@tjmuch.com

引用本文:

贾惠钧,马金涛,孟春柳等. 转移部位不同对广泛期小细胞肺癌胸部放疗价值的影响[J]. 中华放射肿瘤学杂志, 2022, 31(4): 334-339.

Jia Huijun,Ma Jintao,Meng Chunliu et al. Implications of different metastatic sites for thoracic radiation in extensive-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(4): 334-339.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20211019-00418 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I4/334

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. DOI:10.3322/caac.21387.
[2] Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer:veterans administration lung study group versus international association for the study of lung cancer—what limits limited disease?[J]. Lung Cancer, 2002, 37(3):271-276. DOI:10.1016/s0169-5002(02)00072-7.
[3] Tjong MC, Mak DY, Shahi J, et al. Current management and progress in radiotherapy for small cell lung cancer[J]. Front Oncol, 2020, 10:1146. DOI:10.3389/fonc.2020.01146.
[4] Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC):ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24 suppl 6:vi99-105. DOI:10.1093/annonc/mDT178.
[5] Oronsky B, Reid TR, Oronsky A, et al. What's new in sclc? A review[J]. Neoplasia, 2017, 19(10):842-847. DOI:10.1016/j.neo.2017.07.007.
[6] Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance, epidemiologic, and end results database[J]. J Clin Oncol, 2006, 24(28):4539-4544. DOI:10.1200/JCO.2005.04.4859.
[7] Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J]. J Clin Oncol, 2006, 24(13):2038-2043. DOI:10.1200/JCO.2005.04.8595.
[8] Rathod S, Jeremic B, Dubey A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer:A systematic review and meta-analysis of randomised controlled trials[J]. Eur J Cancer, 2019, 110:110-119. DOI:10.1016/j.ejca.2019.01.003.
[9] Slotman BJ, Van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962):36-42. DOI:10.1016/s0140-6736(14)61085-0.
[10] Gore EM, Hu C, Sun AY, et al. Randomized phase Ⅱ study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC):NRG oncology RTOG 0937[J]. J Thorac Oncol, 2017, 12(10):1561-1570. DOI:10.1016/j.jtho.2017.06.015.
[11] Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer:a randomized study[J]. J Clin Oncol, 1999, 17(7):2092-2099. DOI:10.1200/JCO.1999.17.7.2092.
[12] Zhang H, Deng L, Wang X, et al. Metastatic location of extensive stage small-cell lung cancer:implications for thoracic radiation[J]. J Cancer Res Clin Oncol, 2019, 145(10):2605-2612. DOI:10.1007/s00432-019-03000-3.
[13] Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer[J]. Radiother Oncol, 2012, 102(2):234-238. DOI:10.1016/j.radonc.2011.08.042.
[14] Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J]. Cancer, 2011, 117(23):5423-5431. DOI:10.1002/cncr.26206.
[15] Xu LM, Cheng C, Kang M, et al. Thoracic radiotherapy (TRT) improved survival in both oligo-and polymetastatic extensive stage small cell lung cancer[J]. Sci Rep, 2017, 7(1):9255. DOI:10.1038/s41598-017-09775-0.
[16] Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC):the importance of smoking history, socioeconomic and marital statuses, and ethnicity[J]. J Thorac Oncol, 2009, 4(1):37-43. DOI:10.1097/JTO.0b013e31819140fb.
[17] Cai H, Wang H, Li Z, et al. The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients:a large population-based study[J]. Future Oncol, 2018, 14(14):1397-1407. DOI:10.2217/fon-2017-0706.
[18] 罗婧,徐利明,赵路军,等.322例广泛期SCLC不同转移部位的生存分析[J]. 中华放射肿瘤学杂志,2017, 26(1):17-21. DOI:10.3760/cma.j.issn.1004-4221.2017.01.004.
Luo J, Xu LM, Zhao LJ, et al. The survival analysis of different metastasis sites for 332 patients of extensive stage small cell lung cancer[J]. Chin J Radiat Oncol, 2017, 26(1):17-21. DOI:10.3760/cma.j.issn.1004-4221.2017.01.004.
[19] Hellman S, Weichselbaum RR. Oligometastases[J]. J Clin Oncol, 1995, 13(1):8-10. DOI:10.1200/JCO.1995.13.1.8.
[20] Ashworth A, Rodrigues G, Boldt G, et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature[J]. Lung Cancer, 2013, 82(2):197-203. DOI:10.1016/j.lungcan.2013.07.026.
[21] Slotman BJ, van Tinteren H. Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?[J]. Transl Lung Cancer Res, 2015, 4(3):292-294. DOI:10.3978/j.issn.2218-6751.2015.04.07.
[22] Slotman BJ, Faivre-Finn C, van Tinteren H, et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy:a secondary analysis of the phase Ⅲ CREST trial[J]. Lung Cancer, 2017, 108:150-153. DOI:10.1016/j.lungcan.2017.03.007.
[23] Yoon HG, Noh JM, Ahn YC, et al. Higher thoracic radiation dose is beneficial in patients with extensive small cell lung cancer[J]. Radiat Oncol J, 2019, 37(3):185-192. DOI:10.3857/roj.2019.00192.
[24] Xu LM, Zhao LJ, Simone CB 2nd, et al. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer[J]. Radiother Oncol, 2017, 125(2):331-337. DOI:10.1016/j.radonc.2017.10.005.
[25] 罗婧,徐利明,赵路军,等. 不同放化疗组合方案对广泛期SCLC预后影响[J]. 中华放射肿瘤学杂志,2016, 25(11):1166-1171. DOI:10.3760/cma.j.issn.1004-4221.2016.11.005.
Luo J, Xu LM, Zhao LJ, et al. Effects of different chemoradiotherapy schemes on the prognosis of extensive-stage small-cell lung cancer[J]. Chin J Radiat Oncol, 2016, 25(11):1166-1171. DOI:10.3760/cma.j.issn.1004-4221.2016.11.005.
[26] Luo J, Xu L, Zhao L, et al. Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer:important or not?[J]. Radiat Oncol, 2017, 12(1):42. DOI:10.1186/s13014-017-0779-y.